Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ExonHit predicts 2009 US/EU filings for approval of AD (Alzheimer's disease) blood test:

This article was originally published in Clinica

Executive Summary

ExonHit Therapeutics is aiming to apply for the approval of its Alzheimer's disease (AD) blood test in both Europe and the US in 2009. So far, the multigene expression test has been shown to distinguish those with AD from those that have no cognitive impairment. In upcoming studies, the Paris, France firm hopes to prove that the test can differentiate AD from other brain pathologies, such as front temporal dementia, vascular dementia, Parkinson's disease, and also reversible dementias. Initially, the company hopes to market its test in Europe to pharma companies, for use in drug development. Following this, it plans to license the commercial rights to the test to one or more in vitro diagnostic companies. ExonHit claims that some 28 million people suffer from AD worldwide.

You may also be interested in...

QUOTED. 27 November 2020. Agam Sharda.

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts